Bed bugs in Ventura hotel lead to $2-million jury ruling for bitten guests
A bed bug-ridden stay at a Ventura hotel turned into a multimillion-dollar jury payout for two guests who were 'massacre[d] from bed bug bites' during their visit, according to court records.
A jury on Friday ordered the Shores Inn to pay $2 million to Alvaro Gutierrez and Ramiro Sanchez, in what may be one of the largest known bed bug-related jury awards.
'The bed bugs latched onto the Plaintiffs while they slept, sucked their blood until they were gorged, and resisted eradication,' according to the complaint.
A representative for Shores Inn did not immediately respond to a request for comment. An attorney representing the hotel in the suit also did not respond to a request for comment.
According to their complaint, Gutierrez and Sanchez were 'exposed to painful and disgusting bed bug infestations,' and suffered physical, emotional, and mental anguish as a result of their Feb. 7, 2020, stay at the beachside hotel.
'The management was not taking good care of the place,' said Brian Virag, attorney for Gutierrez and Sanchez. 'Turns out, they had experience with bed bugs at that hotel dating back a long time.'
The hotel, located near the 101 Freeway and just a short walk from Ventura Beach, touts easy parking and proximity to the Ventura Pier and the Ventura Harbor.
The complaint, filed in December 2021, alleges the two men rented a room at the hotel and immediately began experiencing bed bug bites.
The suit also alleged that management at the hotel must have been aware of bed bug problems because several online reviews on Google and Yelp warned guests about bed bugs at the hotel, located at 1059 South Seaward Ave. in Ventura.
Despite knowing about the problem, the suit alleges, management failed to eradicate the pests from the hotel, exposing guests to harm.
Gutierrez and Sanchez left the hotel after one night, Virag said, and had to seek medical treatment as a result of the bites.
On May 23, a jury awarded Gutierrez $400,000 in damages for past and future pain, disfigurement, grief, and emotional distress as a result of the injuries. Sanchez was awarded $600,000 in damages, according to court records.
The jury also awarded $500,000 each to the two men in punitive damages.
In 2022, the Disneyland Resort agreed to pay $100,000 to a resort hotel guest in a lawsuit settlement addressing claims she was bitten by bedbugs during a visit in 2018. The following year, a British tourist represented by Virag won a $375,000 award after being attacked by bed bugs during a stay at a Hollywood Hills home.
Virag, an Encino-based attorney who has specialized in bed bug cases filed against hotels and apartments, said the $2-million jury award is the largest one he's seen in bed bug-related cases in his career.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
24 minutes ago
- Yahoo
Sydnexis Announces European Commission Approval of SYD-101, the First and Only Pharmaceutical Treatment for Slowing the Progression of Pediatric Myopia
Exclusive-Licensing Partner Santen Will Commercialize SYD-101 Under the Brand Name Ryjunea® in the European Union DEL MAR, Calif., June 05, 2025--(BUSINESS WIRE)--Sydnexis, Inc., ( a pre-commercial stage biopharmaceutical company today announced that the European Commission (EC) has granted marketing authorization for SYD-101, the company's proprietary low-dose atropine formulation, for slowing the progression of pediatric myopia. As the first and only approved pharmaceutical treatment option to treat myopia progression in EU countries, this approval marks a significant advancement in pediatric eye care. The approval is backed by data from the STAR study, Sydnexis' pivotal Phase 3 clinical trial evaluating its proprietary low-dose atropine formulation to slow the progression of pediatric myopia and the risk of associated co-morbidities in children 3 to 14 years old at treatment initiation. "This marks a significant milestone for Sydnexis and, most importantly, for pediatric patients with progressive myopia, their families, and physicians as the first and only approved pharmaceutical treatment option in Europe," said Perry Sternberg, Chief Executive Officer of Sydnexis. "This approval is an endorsement of the potential benefit SYD-101 can provide to millions of patients globally and reinforces the critical importance of early intervention." The marketing approval from the EC follows the recent positive opinion from the Committee for Medicinal Products for Human Use (CHMP). Santen, a Japan-based company specialized in eye health, offering innovative products and services in over 60 countries worldwide, licensed the rights from Sydnexis to commercialize SYD-101 in the regions of Europe, Middle East, and Africa (EMEA) and will launch SYD-101 under the brand name Ryjunea. "The EU approval of SYD-101 is a recognition of the compelling safety and efficacy data generated from our landmark STAR study," said Patrick Johnson, Ph.D., President of Sydnexis. "This validates the potential benefit that SYD-101 can provide to pediatric myopes in Europe and we are excited about our continued interactions with the Food and Drug Administration (FDA) leading up to our October 23 PDUFA date." Myopia is the most common eye disease in children, impacting approximately one-third of children and adolescents worldwide. By 2050, global prevalence is projected to increase and affect more than 740 million children and adolescents and 5 billion people in total. Once considered a benign refractive condition, even at low levels, myopia is now associated with many serious irreversible sight-threatening co-morbidities later in life. "As a Pediatric Ophthalmologist with a rapidly growing number of myopia patients around the world, the EU approval of SYD-101 is truly exciting and it provides an important new tool for physicians to combat this global epidemic," said Dr. Donny Suh, Gavin Herbert Eye Institute, University of California at Irvine. "The benefits of low-dose atropine have long been recognized in the eye care community, but we now finally have an approved and thoroughly vetted treatment option. This marks a new era in our ability to slow the progression of myopia and protect the vision of millions of children worldwide." About Sydnexis, Inc.: Founded in 2014, Sydnexis, Inc. ( is a privately held, pre-commercial stage biopharmaceutical company based in San Diego, California. Sydnexis recently completed its three-year primary endpoint in the pivotal Phase 3 clinical trial evaluating its proprietary low-dose atropine formulation to slow progression of pediatric myopia and the risk of associated co-morbidities. The Phase 3 clinical trial is now completing the fourth-year randomized withdrawal for exploratory endpoints and third year results will be announced upon completion of the fourth year of the study. The company is venture-backed by four major investors: Visionary Ventures, RA Capital, Longitude Capital, and Bluestem Capital. View source version on Contacts For media inquiries, please contact: media@
Yahoo
29 minutes ago
- Yahoo
Electric truck startup Bollinger exits bankruptcy after paying back founder who sued
Electric truck startup Bollinger Motors has exited U.S. bankruptcy court thanks to more financial aid from parent Mullen Automotive Inc., whose chief has ambitious plans for a rebound set in Michigan. California-based Mullen acquired an additional 21 percent of Bollinger, bringing its ownership stake in the suburban Detroit company to 95 percent, Mullen announced June 2 as it executed its second reverse stock split in as many months to stay compliant with Nasdaq rules on share prices. In tandem with Mullen's transaction, Bollinger was discharged from bankruptcy court, its receiver removed and case dismissed with prejudice, according to a filing in U.S. District Court in Detroit. Mullen Automotive CEO David Michery said the company paid $11 million to Robert Bollinger, who in March sued the company he founded, claiming it was broke and seeking to recover his loan. Sign up for the weekly Automotive News Mobility Report newsletter for the latest developments at the intersection of transportation and technology. Mullen, which has faced a host of financial issues beyond Bollinger, is all-in on the EV startup, Michery said June 4 during an interview with Automotive News and affiliate Crain's Detroit Business. Bollinger Motors — despite the spat with its namesake — will persevere as a brand that 'will outlast everyone,' Michery vowed at the startup's Oak Park, Mich., headquarters. 'You can't blame Bollinger for the current market, you can't blame Bollinger for tariffs, you can't blame Bollinger for the disruption that occurred with Robert filing this frivolous lawsuit,' Michery said. 'That hurt the company.' Now, Mullen is putting its chips on Bollinger Motors to weather the storm. Michery said production of Class 4 trucks would resume in 8 to10 weeks and that its staff of about 85 in metro Detroit would soon swell in line with a predicted increase in demand — though that remains in question with a stagnant market. Mullen will close its engineering base in Irvine, Calif., and consolidate it to the company's tech center near Detroit in Troy, Mich., where 40-50 employees will be added, Michery said. 'I want all engineering, all manufacturing, everything in the state of Michigan,' he said. While Michery serves as CEO of Bollinger Motors, the company's daily operations will be overseen by James Taylor, who will return to the company as a consultant after departing in March. Another priority is cleaning up the company's supply chain. Bollinger Motors has been sued by several suppliers claiming they were being stiffed by the startup. Michery said he is in the process of paying debts, including to contract manufacturer Roush, which makes the class 4 trucks for Bollinger. Mullen's earnings reports to the SEC seem to indicate big financial trouble. It lost $162 million on revenue of $7.9 million in the first quarter; it posted a $115 million loss on revenue of $2.9 million in the prior quarter. The company lost its 675,000-square-foot former AM General factory in Mishawaka, Ind., last month to settle a financial dispute with creditor GEM Yield Bahamas Ltd. However, Michery said the company has ample liquidity, including a $150 million equity line allowing the company to use its stock as currency — an instrument approved by the SEC and shareholders. 'Picture a credit card,' he said. 'Mullen has a $150 million credit card that it can use at will.' Mullen's 1-for-100 reverse stock split executed Monday was designed to bring its stock price above $1 per share to meet Nasdaq requirements. Financial adviser Alex Calderone said the move is window dressing and does not solve underlying business performance issues. 'I would not surmise that would impact company valuation at all or shareholder rights at all,' Calderone said. 'It just appears to be a cosmetic change to be able to adjust the share price. … It's like if I traded you a hundred dollar bill for a hundred singles.' On Wednesday, Mullen's stock shot up to above $16 per share, tripling its value over the course of a day, as Michery pointed out after pulling up the market summary on his phone. He said: 'They knew we were coming out here to put Bollinger back in business.' Have an opinion about this story? Tell us about it and we may publish it in print. Click here to submit a letter to the editor. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
32 minutes ago
- Yahoo
Homeland Security arrests 11 people, Bus driver speaks out on safety issues, Warm weather returns, Mixed-income housing project, ‘La Chicanita' honored
City of Albuquerque fines Comcast over incomplete jobs and exposed wires Grindstone Lake restocked with rainbow trout New Mexico man found guilty of kidnapping and conspiracy Teen charged in Albuquerque bicyclist's death will stay in custody Two Albuquerque restaurants make Yelp's 'Top 50 Cheap Eats' list Lavender in the Village Festival moving to new space in 2025 [1] Homeland Security: 11 people arrested at New Mexico dairy were 'undocumented' – The United States Department of Homeland Security Investigations arrested 11 undocumented workers after executing a search warrant at a New Mexico dairy farm. HSI said the migrants working at the Outlook Dairy Farm in Lovington had counterfeit green cards and used them to illegally obtain work. [2] Albuquerque bus driver speaks out on her experience of safety issues on Central route – While ABQ Ride said it has improved security on city buses, some drivers are saying they are still dealing with safety hazards at work. Denise Muniz Archibeque has driven a bus for the past year, mainly on Central Ave. She said drivers endure verbal abuse, threats, and frequent physical assaults. She called for a change to the city's Zero Fares Program, which allows anyone to ride the bus for free. City Councilor Nichole Rogers rejected the idea. ABQ Ride declined an interview but said that within the past year, they've invested in protective barriers around bus drivers and tightened rules for rider behavior. [3] Storm system moves out of New Mexico, warm temperatures return – Muggy conditions are still present in the wake of Wednesday's widespread thunderstorms with lingering rainfall across far-Southeast New Mexico, as well as parts of the Four Corners, with somewhat-gusty winds. Near-freezing temperatures are confined to the higher peaks of the Northern Mountains, while elsewhere, is mostly starting off in the upper 40s, 50s, and 60s. [4] New mixed-income housing project underway in Albuquerque – Construction is underway on a new mixed-income apartment complex in Albuquerque. Wednesday, Sol Housing and city officials broke ground on the complex located at Central Ave. and Alcazar St., just east of Louisiana. They say it is designed to provide affordable housing for older adults and those with accessibility needs. [5] Famed singer and lawyer Debbie 'La Chicanita' Martinez honored with historic marker – A program that shares the stories of remarkable women in New Mexico's history is honoring a late singer hailed as a trailblazer in the New Mexico music scene. Debbie 'La Chicanita' Martinez was a household name for Hispano families in the southwest and a star of the unique Nuevo Mexico sound of the 50s. The late singer is now being honored with a historic marker at EXPO New Mexico for her legacy in transforming New Mexican music and breaking into a male-dominated mariachi scene. After losing her hearing in her early 20s, Martinez earned degrees in business and law. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
